Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0051 | Etodolac

Molecular Formula C17H21NO3
Molecular Weight 287.35
Structure
State solid
Clearance * Oral cl=49.1 mL/h/kg [Normal healthy adults] * Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)] * Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)] * Oral cl=45.7 mL/h/kg [Eldery (>65 years)] * Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)] * Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]
Volume of distribution * 390 mL/kg
Route of elimination It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.
Protein binding > 99% bound, primarily to albumin
Half life Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours
Absorption Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.
Description non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties; inhibit prostaglandin synthesis

M

M01AB08 Etodolac


[M01AB] Acetic acid derivatives and related substances


[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS


[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS


[M] Musculoskeletal system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
UNCOUPLING isolated mitochondria increase 56
UNCOUPLING rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay Negative 53
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay Negative 53

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 48 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]


H319 (89.58%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P264, P270, P280, P301+P310, P305+P351+P338, P321, P330, P337+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Arthritis

  • Diabetes mellitus

  • Juvenile idiopathic arthritis

  • Osteoarthritis

  • Pain

  • Rheumatoid arthritis

  • Dyspepsia (0.1)

    • (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
    (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid
    1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid 1,8-Diethyl-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid
    1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
    2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid. 2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid
    340E254 41340-25-4 AB00052194
    AB00052194_17 AB0012214 AC-4231
    AK550845 AKOS015838610 ANW-42024
    AY 24,236 AY 24236 AY 24236;AY-24,236
    AY-24,236 AY-24236 AY-24236
    AY24,236 AY24236 BCP28411
    BDBM50016799 BPBio1_000333 BRD-A74667430-001-05-3
    BRD-A74667430-001-15-2 BSPBio_000301 BSPBio_003138
    C06991 CAS-41340-25-4 CCG-39005
    CCRIS 3923 CE0096 CHEBI:4909
    CHEMBL622 CPD000058443 CS-0832
    CTK4I4719 D00315 DB00749
    DSSTox_CID_615 DSSTox_GSID_20615 DSSTox_RID_75691
    DTXSID9020615 DivK1c_000147 E 0516
    E0858 EU-0100479 Edolan
    Etodlic Acid Etodolac (JP17/USP/INN) Etodolac [USAN:INN:BAN]
    Etodolac [USAN:USP:INN:BAN] Etodolac for peak identification, European Pharmacopoeia (EP) Reference Standard Etodolac(Lodine)
    Etodolac, European Pharmacopoeia (EP) Reference Standard Etodolac, United States Pharmacopeia (USP) Reference Standard Etodolac,(S)
    Etodolaco Etodolaco [INN-Spanish] Etodolacum
    Etodolacum [INN-Latin] Etodolic acid Etodolsaure
    F2173-0681 FT-0607046 GTPL7185
    HMS1568P03 HMS1921B09 HMS2092O20
    HMS2095P03 HMS2231D04 HMS3259P10
    HMS3261O20 HMS3374G09 HMS3712P03
    HMS500H09 HY-76251 Hypen
    IDI1_000147 K-8734 KBio1_000147
    KBio2_001724 KBio2_004292 KBio2_006860
    KBio3_002358 KBioGR_000680 KBioSS_001724
    KS-0000000W KS-1056 LP00479
    LS-7393 Lodine Lodine (TN)
    Lodine SR Lodine XL Lopac0_000479
    MFCD00133313 MLS000028474 MLS001077315
    MLS006011566 NC00718 NCGC00015399-03
    NCGC00015399-04 NCGC00015399-05 NCGC00015399-06
    NCGC00015399-07 NCGC00015399-08 NCGC00015399-09
    NCGC00015399-11 NCGC00015399-12 NCGC00015399-13
    NCGC00015399-15 NCGC00015399-16 NCGC00016849-01
    NCGC00089769-02 NCGC00089769-03 NCGC00089769-04
    NCGC00089769-05 NCGC00089769-06 NCGC00089769-07
    NCGC00259767-01 NCGC00261164-01 NINDS_000147
    NNYBQONXHNTVIJ-UHFFFAOYSA-N NSC 282126 NSC-282126
    NSC-757821 NSC282126 NSC757821
    Opera_ID_1774 Osteluc Pharmakon1600-01501005
    Prestwick0_000231 Prestwick1_000231 Prestwick2_000231
    Prestwick3_000231 Prestwick_209 Pyrano(3,4,b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-
    Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl- Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-
    Pyrano[3, 1,8-diethyl-1,3,4,9-tetrahydro- Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- Q-201099
    Q2465218 RAK-591 RTR-036749
    Ramodar SAM002589968 SBI-0050463.P003
    SCHEMBL3903 SMR000058443 SPBio_001374
    SPBio_002222 SPECTRUM1501005 SR-01000000100
    SR-01000000100-2 SR-01000000100-4 SR-01000000100-7
    Spectrum2_001387 Spectrum3_001429 Spectrum4_000410
    Spectrum5_001347 Spectrum_001244 TR-036749
    Tedolan Tox21_110644 Tox21_110644_1
    Tox21_202218 Tox21_500479 Ultradol
    Z1820178466 Zedolac [1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid
    etodolac etodolac o

    DrugBank Name Etodolac
    DrugBank DB00749
    CAS Number 109518-50-5, 110078-46-1, 41340-25-4, 849630-94-0
    PubChem Compound 3308
    KEGG Compound ID C06991
    KEGG Drug D00315
    PubChem.Substance 46505184
    ChEBI 4909
    PharmGKB PA449550
    ChemSpider 3192
    BindingDB 50016799.0
    TTD DAP000778
    Wikipedia Etodolac
    DPD 1880

    1. Dykens et al. (2007)